Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Notification for a New Dietary Ingredient, 69095-69097 [2013-27536]
Download as PDF
Federal Register / Vol. 78, No. 222 / Monday, November 18, 2013 / Notices
Dated: November 12, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2013–27503 Filed 11–15–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1119]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Food Canning
Establishment Registration, Process
Filing, and Recordkeeping for Acidified
Foods and Thermally Processed LowAcid Foods in Hermetically Sealed
Containers; Extension of Comment
Period
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; extension of comment
period.
The Food and Drug
Administration (FDA or we) is
extending the comment period for the
information collection entitled ‘‘Food
Canning Establishment Registration,
Process Filing, and Recordkeeping for
Acidified Foods and Thermally
Processed Low-Acid Foods in
Hermetically Sealed Containers’’ that
appeared in the Federal Register of
September 18, 2013 (78 FR 57391). In
the notice requesting comment on the
proposed information collection, we
requested comments on the information
collection provisions that are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (PRA). We are
taking this action in response to a
request for an extension to allow
interested persons additional time to
submit comments on the proposed
information collection.
DATES: FDA is extending the comment
period on the proposed information
collection. Submit either electronic or
written comments by February 18, 2014.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:33 Nov 15, 2013
Jkt 232001
I. Background
In the Federal Register of September
18, 2013 (78 FR 57391), FDA published
a notice with a 60-day comment period
to request comment on a proposed
collection of information related to
‘‘Food Canning Establishment
Registration, Process Filing, and
Recordkeeping for Acidified Foods and
Thermally Processed Low-Acid Foods
in Hermetically Sealed Containers.’’
Under the PRA (44 U.S.C. 3501–3520),
Federal Agencies must obtain approval
from the Office of Management and
Budget (OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval.
We have received a request to extend
the comment period for the proposed
collection of information. The request
noted that we intend to issue a draft
guidance document further explaining
the forms that are the subject of the
collection of information and requested
that the comment period for the
proposed collection of information be
extended to match the comment period
that will be announced in a future
notice requesting comments on such a
draft guidance document. The requestor
expected that a likely comment period
for the draft guidance would be 60 days.
We have considered the request and
are extending the comment period for
the information collection for 90 days,
until February 18, 2014. We believe that
a 90-day extension allows adequate time
for interested persons to submit
comments without significantly
delaying our submission of the
proposed collection of information to
OMB for review under the PRA. We are
not granting the specific request to
extend the comment period to match the
date when we publish a notice of
availability for a related draft guidance
because we cannot say with certainty
when that notice will publish. However,
we expect to issue that notice in a
timely manner such that we would
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
69095
announce a comment period until
approximately February 18, 2014. In
addition, we note that comments are
welcome on guidance documents at any
time (21 CFR 10.115(g)(5)).
II. Request for Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: November 13, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–27537 Filed 11–15–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0878]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Premarket
Notification for a New Dietary
Ingredient
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by December
18, 2013.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0330. Also
include the FDA docket number found
in brackets in the heading of this
document.
SUMMARY:
E:\FR\FM\18NON1.SGM
18NON1
69096
Federal Register / Vol. 78, No. 222 / Monday, November 18, 2013 / Notices
FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
FOR FURTHER INFORMATION CONTACT:
Premarket Notification for a New
Dietary Ingredient (NDI)—21 CFR 190.6
(OMB Control Number 0910–0330)—
Extension
Section 413(a) of the Federal Food,
Drug, and Cosmetic Act (FD&C Act) (21
U.S.C. 350b(a)) provides that at least 75
days before the introduction or delivery
for introduction into interstate
commerce of a dietary supplement that
contains an NDI, a manufacturer or
distributor of dietary supplements or of
an NDI is to submit to us (as delegate
for the Secretary of Health and Human
Services) information upon which the
manufacturer or distributor has based its
conclusion that a dietary supplement
containing an NDI will reasonably be
expected to be safe. Part 190 (21 CFR
part 190) implements these statutory
provisions. Section 190.6(a) requires
each manufacturer or distributor of a
dietary supplement containing an NDI,
or of an NDI, to submit to the Office of
Nutrition, Labeling, and Dietary
Supplements notification of the basis for
their conclusion that said supplement or
ingredient will reasonably be expected
to be safe. Section 190.6(b) requires that
the notification include the following:
(1) The complete name and address of
the manufacturer or distributor, (2) the
name of the NDI, (3) a description of the
dietary supplements that contain the
NDI, and (4) the history of use or other
evidence of safety establishing that the
dietary ingredient will reasonably be
expected to be safe.
The notification requirements
described previously are designed to
enable us to monitor the introduction
into the food supply of NDIs and dietary
supplements that contain NDIs, in order
to protect consumers from the
introduction of unsafe dietary
supplements into interstate commerce.
We use the information collected under
these regulations to help ensure that a
manufacturer or distributor of a dietary
supplement containing an NDI is in full
compliance with the FD&C Act. We are
currently developing an electronic
means for submitting this information.
Description of Respondents: The
respondents to this collection of
information are firms in the dietary
supplement industry, including dietary
supplement and dietary ingredient
manufacturers, packagers and repackagers, holders, labelers and relabelers, distributors, warehouses,
exporters, and importers.
In the Federal Register of August 26,
2013 (78 FR 52773), FDA published a
60-day notice requesting public
comment on the proposed collection of
information; two comments were
received with one containing multiple
comments. Some comments were
outside the scope of the four collection
of information topics being solicited and
therefore will not be discussed in this
document.
One comment suggested providing
drop-down menus to facilitate data
entry. FDA appreciates this suggestion
and will continue to consider various
configurations for submitting
information in electronic form that are
most effective and efficient for
respondents. Another comment stated
that FDA’s estimate of 20 hours per
notification is not accurate. The
comment indicated that 40 to 60 hours
were required to extract and summarize
relevant information from the firm’s
files, and that an additional 20 to 40
hours was needed to format the
information to meet NDI requirements.
FDA deliberated over this comment, but
believes that collecting and compiling
data under applicable regulatory
requirements for the premarket
notification program places a minimal
burden on respondents. As noted both
in our August 26, 2013, notice and in
this document, § 190.6(a) requires each
manufacturer or distributor of an NDI,
or dietary supplement containing an
NDI, to submit notification of the basis
for their conclusion that the supplement
or ingredient will reasonably be
expected to be safe. Because we are
requesting only that information that the
manufacturer or distributor should have
already developed, we believe that 20
hours per submission is an appropriate
burden estimate.
Both comments note that in the
Federal Register of July 5, 2011 (76 FR
39111), FDA issued a draft guidance
entitled ‘‘Dietary Supplements: New
Dietary Ingredient Notifications and
Related Issues’’ (available at https://
www.fda.gov/Food/Guidance
Regulation/GuidanceDocuments
RegulatoryInformation/Dietary
Supplements/ucm257563.htm) and
suggested that FDA underestimated the
reporting burden of the notification
procedures under § 190.6 because we
failed to take into account the
provisions of the draft guidance. FDA
considered this response but submits
that the notification procedure
requirements set forth in its regulations
at § 190.6 remain unchanged. The
collection of information in this instant
analysis is exclusive of the draft
guidance and pertains only to the
subject regulations. However, as stated
in the notice of availability for the draft
guidance, FDA does intend to publish a
60-day notice inviting comment on the
information collection burden
associated with that document and will
carefully evaluate all comments it
receives.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR section
Number of
respondents
Number of responses
per respondent
Total annual
responses
Average burden per
response
Total hours
190.6
55
1
55
20
1,100
mstockstill on DSK4VPTVN1PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
We believe that there will be minimal
burden on the industry to generate data
to meet the requirements of the
premarket notification program because
we are requesting only that information
that the manufacturer or distributor
should already have developed to
satisfy itself that a dietary supplement
VerDate Mar<15>2010
17:33 Nov 15, 2013
Jkt 232001
containing an NDI is in full compliance
with the FD&C Act. In the past,
commenters argued that our burden
estimate is too low. Section 190.6(a)
requires each manufacturer or
distributor of a dietary supplement
containing an NDI, or of an NDI, to
submit notification of the basis for their
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
conclusion that said supplement or
ingredient will reasonably be expected
to be safe. Section 190.6 requests simply
the extraction and summarization of the
safety data that should have already
been developed by the manufacturer or
distributor. Thus, we estimate that
extracting and summarizing the relevant
E:\FR\FM\18NON1.SGM
18NON1
69097
Federal Register / Vol. 78, No. 222 / Monday, November 18, 2013 / Notices
information from the company’s files,
and presenting it in a format that will
meet the requirements of section 413 of
the FD&C Act will require a burden of
approximately 20 hours of work per
submission.
We estimate that 55 respondents will
submit one premarket notification each
and that it will take a respondent 20
hours to prepare the notification, for a
total of 1,100 hours. The estimated
number of premarket notifications and
hours per response is an average based
on our experience with notifications
received during the last 3 years and
information from firms that have
submitted recent premarket
notifications.
Dated: November 13, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–27536 Filed 11–15–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Recombinant DNA
Advisory Committee.
Date: December 4–5, 2013.
Time: December 04, 2013, 12:30 p.m. to
5:45 p.m.
Agenda: The NIH Recombinant DNA
Advisory Committee (RAC) will review and
discuss selected human gene transfer
protocols and related data management
activities. Please check the meeting agenda at
OBA Meetings Page (available at the
following URL: https://oba.od.nih.gov/rdna_
rac/rac_meetings.html) for more information.
Place: National Institutes of Health,
Rockledge II, Conference Room 9100, 6701
Rockledge Drive, Bethesda, MD 20892.
Time: December 05, 2013, 8:30 a.m. to
12:45 p.m.
Agenda: The NIH Recombinant DNA
Advisory Committee (RAC) will review and
discuss selected human gene transfer
protocols and related data management
activities. Please check the meeting agenda at
OBA Meetings Page (available at the
VerDate Mar<15>2010
17:33 Nov 15, 2013
Jkt 232001
following URL: https://oba.od.nih.gov/rdna_
rac/rac_meetings.html) for more information.
Place: National Institutes of Health,
Rockledge II, Conference Room 9100, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Chezelle George, Office of
Biotechnology Activities, Office of Science
Policy/OD, National Institutes of Health,
6705 Rockledge Drive, Room 750, Bethesda,
MD 20892, 301–496–9838, georgec@
od.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
oba.od.nih.gov/rdna/rdna.html, where an
agenda and any additional information for
the meeting will be posted when available.
OMB’s ‘‘Mandatory Information
Requirements for Federal Assistance Program
Announcements’’ (45 FR 39592, June 11,
1980) requires a statement concerning the
official government programs contained in
the Catalog of Federal Domestic Assistance.
Normally NIH lists in its announcements the
number and title of affected individual
programs for the guidance of the public.
Because the guidance in this notice covers
virtually every NIH and Federal research
program in which DNA recombinant
molecule techniques could be used, it has
been determined not to be cost effective or
in the public interest to attempt to list these
programs. Such a list would likely require
several additional pages. In addition, NIH
could not be certain that every Federal
program would be included as many Federal
agencies, as well as private organizations,
both national and international, have elected
to follow the NIH Guidelines. In lieu of the
individual program listing, NIH invites
readers to direct questions to the information
address above about whether individual
programs listed in the Catalog of Federal
Domestic Assistance are affected.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: November 12, 2013.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–27455 Filed 11–15–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Performance Review Board Members
Title 5, U.S.C. Section 4314(c)(4) of
the Civil Service Reform Act of 1978,
Public Law 95–454, requires that the
appointment of Performance Review
Board Members be published in the
Federal Register.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
The following persons may be named
to serve on the Performance Review
Boards or Panels, which oversee the
evaluation of performance appraisals of
Senior Executive Service members of
the Department of Health and Human
Services.
LAST NAME
ETZINGER .....................
CLARK ............................
HENDRIKSSON .............
DEL VECCHIO ...............
ENOMOTO .....................
DELPHIN-RITTMON ......
HARDING .......................
DELANY .........................
BEADLE .........................
KADE ..............................
POWER ..........................
BENOR ...........................
FLEMING ........................
FIRST NAME
MICHAEL
WESTLEY
MARLA
PAOLO
KANA
MIRIAM
FRANCES
PETER
MIRTHA
DARYL
KATHRYN
DAVID
MARY
Michael Etzinger,
Executive Officer and Director, Office of
Management, Technology and Operations.
Janine Denis Cook,
Chemist, Division of Workplace Programs,
Center for Substance Abuse Prevention,
Substance Abuse and Mental Health Services
Administration.
[FR Doc. 2013–27423 Filed 11–15–13; 8:45 am]
BILLING CODE 4151–17–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID: FEMA–2013–0047; OMB No.
1660–NEW]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
The Federal Emergency
Management Agency, as part of its
continuing effort to reduce paperwork
and respondent burden, invites the
general public and other Federal
agencies to take this opportunity to
comment on a new information
collection. In accordance with the
Paperwork Reduction Act of 1995, this
notice seeks comments concerning the
SalesForce Customer Relationship
Management System.
DATES: Comments must be submitted on
or before January 17, 2014.
ADDRESSES: To avoid duplicate
submissions to the docket, please use
only one of the following means to
submit comments:
SUMMARY:
E:\FR\FM\18NON1.SGM
18NON1
Agencies
[Federal Register Volume 78, Number 222 (Monday, November 18, 2013)]
[Notices]
[Pages 69095-69097]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-27536]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0878]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Premarket
Notification for a New Dietary Ingredient
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing
that a proposed collection of information has been submitted to the
Office of Management and Budget (OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
December 18, 2013.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0330.
Also include the FDA docket number found in brackets in the heading of
this document.
[[Page 69096]]
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville,
MD 20850, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Premarket Notification for a New Dietary Ingredient (NDI)--21 CFR 190.6
(OMB Control Number 0910-0330)--Extension
Section 413(a) of the Federal Food, Drug, and Cosmetic Act (FD&C
Act) (21 U.S.C. 350b(a)) provides that at least 75 days before the
introduction or delivery for introduction into interstate commerce of a
dietary supplement that contains an NDI, a manufacturer or distributor
of dietary supplements or of an NDI is to submit to us (as delegate for
the Secretary of Health and Human Services) information upon which the
manufacturer or distributor has based its conclusion that a dietary
supplement containing an NDI will reasonably be expected to be safe.
Part 190 (21 CFR part 190) implements these statutory provisions.
Section 190.6(a) requires each manufacturer or distributor of a dietary
supplement containing an NDI, or of an NDI, to submit to the Office of
Nutrition, Labeling, and Dietary Supplements notification of the basis
for their conclusion that said supplement or ingredient will reasonably
be expected to be safe. Section 190.6(b) requires that the notification
include the following: (1) The complete name and address of the
manufacturer or distributor, (2) the name of the NDI, (3) a description
of the dietary supplements that contain the NDI, and (4) the history of
use or other evidence of safety establishing that the dietary
ingredient will reasonably be expected to be safe.
The notification requirements described previously are designed to
enable us to monitor the introduction into the food supply of NDIs and
dietary supplements that contain NDIs, in order to protect consumers
from the introduction of unsafe dietary supplements into interstate
commerce. We use the information collected under these regulations to
help ensure that a manufacturer or distributor of a dietary supplement
containing an NDI is in full compliance with the FD&C Act. We are
currently developing an electronic means for submitting this
information.
Description of Respondents: The respondents to this collection of
information are firms in the dietary supplement industry, including
dietary supplement and dietary ingredient manufacturers, packagers and
re-packagers, holders, labelers and re-labelers, distributors,
warehouses, exporters, and importers.
In the Federal Register of August 26, 2013 (78 FR 52773), FDA
published a 60-day notice requesting public comment on the proposed
collection of information; two comments were received with one
containing multiple comments. Some comments were outside the scope of
the four collection of information topics being solicited and therefore
will not be discussed in this document.
One comment suggested providing drop-down menus to facilitate data
entry. FDA appreciates this suggestion and will continue to consider
various configurations for submitting information in electronic form
that are most effective and efficient for respondents. Another comment
stated that FDA's estimate of 20 hours per notification is not
accurate. The comment indicated that 40 to 60 hours were required to
extract and summarize relevant information from the firm's files, and
that an additional 20 to 40 hours was needed to format the information
to meet NDI requirements. FDA deliberated over this comment, but
believes that collecting and compiling data under applicable regulatory
requirements for the premarket notification program places a minimal
burden on respondents. As noted both in our August 26, 2013, notice and
in this document, Sec. 190.6(a) requires each manufacturer or
distributor of an NDI, or dietary supplement containing an NDI, to
submit notification of the basis for their conclusion that the
supplement or ingredient will reasonably be expected to be safe.
Because we are requesting only that information that the manufacturer
or distributor should have already developed, we believe that 20 hours
per submission is an appropriate burden estimate.
Both comments note that in the Federal Register of July 5, 2011 (76
FR 39111), FDA issued a draft guidance entitled ``Dietary Supplements:
New Dietary Ingredient Notifications and Related Issues'' (available at
https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/ucm257563.htm) and suggested that FDA underestimated the reporting
burden of the notification procedures under Sec. 190.6 because we
failed to take into account the provisions of the draft guidance. FDA
considered this response but submits that the notification procedure
requirements set forth in its regulations at Sec. 190.6 remain
unchanged. The collection of information in this instant analysis is
exclusive of the draft guidance and pertains only to the subject
regulations. However, as stated in the notice of availability for the
draft guidance, FDA does intend to publish a 60-day notice inviting
comment on the information collection burden associated with that
document and will carefully evaluate all comments it receives.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
190.6 55 1 55 20 1,100
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
We believe that there will be minimal burden on the industry to
generate data to meet the requirements of the premarket notification
program because we are requesting only that information that the
manufacturer or distributor should already have developed to satisfy
itself that a dietary supplement containing an NDI is in full
compliance with the FD&C Act. In the past, commenters argued that our
burden estimate is too low. Section 190.6(a) requires each manufacturer
or distributor of a dietary supplement containing an NDI, or of an NDI,
to submit notification of the basis for their conclusion that said
supplement or ingredient will reasonably be expected to be safe.
Section 190.6 requests simply the extraction and summarization of the
safety data that should have already been developed by the manufacturer
or distributor. Thus, we estimate that extracting and summarizing the
relevant
[[Page 69097]]
information from the company's files, and presenting it in a format
that will meet the requirements of section 413 of the FD&C Act will
require a burden of approximately 20 hours of work per submission.
We estimate that 55 respondents will submit one premarket
notification each and that it will take a respondent 20 hours to
prepare the notification, for a total of 1,100 hours. The estimated
number of premarket notifications and hours per response is an average
based on our experience with notifications received during the last 3
years and information from firms that have submitted recent premarket
notifications.
Dated: November 13, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-27536 Filed 11-15-13; 8:45 am]
BILLING CODE 4160-01-P